MAPT and Alzheimer disease: Current diagnostic approaches for AD rely on a combination of methods, including the Mini‐Mental State Examination (MMSE), measurements of Aβ and Tau levels in the blood and CSF, structural brain imaging via magnetic resonance imaging (MRI), and positron emission tomography (PET) scanning to assess glucose metabolism in the brain [212, 213].